POPULARITY
In this episode, we speak with Mary Wells, who was diagnosed with primary myelofibrosis in 2018, a rare blood cancer… The post Choosing the Path Forward: Shared Decisions in Myelofibrosis Care first appeared on The Bloodline with LLS.
Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics: Introduction (0:00) New Biology of Myelofibrosis (1:55) Novel Regulatory T-Cell Infusion Therapy (14:57) Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39) BET Inhibitors: Pelabresib (42:03) Navtemadlin (53:20) CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 1: Current Management of Myelofibrosis (MF) — Professor Claire Harrison CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 2: Novel Investigational Strategies — John Mascarenhas, MD CME information and select publications
Professor Claire Harrison from the Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here.
Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, including the following topics: Systemic Mastocytosis — Dr Bose (0:00) Myelofibrosis — Dr Kuykendall (24:46) CME information and select publications
Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis. CME information and select publications here.
Drs. Pemmaraju and Bose discuss the revised International Working Group criteria for anemia response in patients with myelofibrosis, outlining new definitions for transfusion status, gender-specific hemoglobin thresholds, and benchmarks for major and minor responses.
Drs. Bose and Pemmaraju discuss leukemic transformation in patients with myelofibrosis, reviewing its incidence, as well as risk factors, treatment, and prognosis.
Drs. Bose and Pemmaraju review secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia and how it differs from primary myelofibrosis that develops de novo.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.
Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics: Overview of the current JAK inhibitor landscape (0:00) Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02) Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17) Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13) Available clinical data with novel BET inhibitors (15:00) Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50) Emerging efficacy and safety findings reported with imetelstat for MF (18:57) Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15) Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05) Other novel agents and strategies under investigation for MF (26:06) CME information and select publications
Featuring an interview with Dr Raajit K Rampal, including the following topics: Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00) Novel research strategies involving CDK4/6 inhibitors for MF (8:03) Implications of the JUMP study for clinical practice (10:00) Therapeutic switching strategies with JAK inhibitors for MF (12:17) Clinical rationale for the use of luspatercept and elritercept for MF (15:35) Emerging clinical data involving BET inhibitors for MF (16:57) Tolerability concerns with selinexor in patients with MF (20:01) Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32) Additional novel strategies under clinical investigation for MF (25:52) Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40) Management of polycythemia vera and essential thrombocythemia (34:27) General management principles for myeloproliferative neoplasms (37:53) CME information and select publications
Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.
A phase 3 study showed that combining pelabresib with ruxolitinib significantly improved spleen volume reduction and symptom relief in myelofibrosis patients compared to ruxolitinib alone, offering a promising new treatment option. Long-term use of gantenerumab may delay Alzheimer's dementia onset in individuals with inherited Alzheimer's, supporting the amyloid hypothesis and paving the way for future prevention strategies. Phase 3 trials demonstrated that povorcitinib, an oral JAK1 inhibitor, significantly improved clinical outcomes in adults with moderate to severe hidradenitis suppurativa, potentially offering a new treatment option. Research linked red meat allergy to bites from additional tick species, expanding the geographic risk area and highlighting the need for clinicians to consider this diagnosis in patients with unexplained allergic symptoms following tick bites.
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions
Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53) Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45) Managing MF for Patients with Anemia — Dr Yacoub (59:47) Future Directions in the Management of MF — Dr Fleischman (1:27:53) CME information and select publications
Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis.
Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Dr Angela G Fleischman from UC Irvine Health in Irvine, California, Dr Abdulraheem Yacoub from The University of Kansas Cancer Center in Westwood and Dr Andrew T Kuykendall from Moffitt Cancer Center in Tampa, Florida, discuss recent updates on available and novel treatment strategies for myelofibrosis, moderated by Dr Kuykendall. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHMF24).
Drs. Komrokji and Kuykendall review the evolution of clinical trial endpoints in myelofibrosis studies. They discuss traditional measures of disease control, such as spleen volume reduction and hematologic response, as well as expanded endpoints that reflect the biological and symptomatic aspects of myelofibrosis.
Andrew Kuykendall, MD and Rami Komrokji, MD discuss cytopenic myelofibrosis, reviewing how these patients typically present. They also cover mutational burden, specific treatment strategies, and prognosis in patients with the cytopenic phenotype.
Dr. Angela Fleischman and Dr. Gabriella Hobbs discussed two intriguing abstracts presented at the ASH 2024 Annual Meeting about emerging treatments for myelofibrosis. The first study, led by Dr. Lucia Massarova, explored the safety and preliminary efficacy of cord blood-derived CXCR4-enriched T-regulatory cells in patients with suboptimal response to ruxolitinib, showing minimal adverse events and potential improvements in hemoglobin, spleen size, and symptoms. The second study evaluated nuvusertib (TP3654), a selective PIM1 kinase inhibitor, in patients with relapsed/refractory myelofibrosis, demonstrating stable hemoglobin and platelet levels, symptom and spleen volume improvement, and preliminary evidence of fibrosis and cytokine response.
In this episode of the Peer Direct Specialist Spotlight, Gabriella Hobbs, MD and Angela Fleischman, MD, PhD discuss updates from the ASH 2024 annual meeting on emerging therapies for myelofibrosis, focusing on two agents: ilritracept and PXS-5505. Ilritracept, a modified ligand trap, showed promise in improving anemia, transfusion burden, spleen size, and symptoms, with data suggesting potential benefits in addressing ruxolitinib-associated cytopenias. PXS-5505, a pan-LOX inhibitor with antifibrotic effects, was evaluated in combination with ruxolitinib, highlighting the role of antifibrotic agents as adjunctive therapies.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/EMK865. CME/MOC/AAPA credit will be available until January 5, 2026.Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.Disclosure information is available at the beginning of the video presentation.
Featuring perspectives from Dr Stephen T Oh, moderated by Dr Stephen “Fred” Divers CME information and select publications
Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).
Dr Stephen T Oh shares his perspectives on the evolving therapeutic landscape for patients with myelofibrosis.
John Mascarenhas, MD and Kathryn Johnson, DNP, MSc, FNP‑BC discuss the common signs and symptoms seen in patients with myelofibrosis and share insights into how they go about addressing them. They review anemia and splenomegaly, platelet-related symptoms of bleeding and thrombosis, and constitutional symptoms.
Dr. Mascarenhas and Kathryn Johnson review important considerations for referring physicians in clinical trials for myelofibrosis. They cover timing for referral, referral pathways, and appropriate patients, as well as assessments, monitoring, and even logistical considerations.
In this week's episode we'll learn more about the role of ERG loss-of-function variants in bone marrow failure and hematological malignancies, a proposed pathway linking factor 11 activation to increased vascular permeability during inflammation, and new clinical criteria for diagnosing anemia, defining transfusion-dependence, and evaluating anemia treatment responses in patients with myelofibrosis.Featured Articles:Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predispositionCoagulation factor XI regulates endothelial cell permeability and barrier function in vitro and in vivoProposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
In today's episode, supported by Sobi, we had the pleasure of speaking with Aaron T. Gerds, MD, MS, and James K. McCloskey, MD, about myelofibrosis treatment advances. Dr Gerds is an assistant professor in the Department of Medicine in the School of Medicine, as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center in Cleveland, Ohio. He is also a physician in the Department of Hematology and Medical Oncology at Cleveland Clinic. Dr McCloskey is the interim chief of the Division of Leukemia at Hackensack John Theurer Cancer Center in New Jersey. In our exclusive interview, Drs Gerds and McCloskey discussed factors that influence their choice between the variety of JAK inhibitors that are FDA approved for patients with myelofibrosis, tips for symptom management in this disease, and emerging myelofibrosis research to look out for.